MARLBOROUGH, Mass.,
Oct. 3, 2016 /PRNewswire/
-- Hologic, Inc. (Nasdaq: HOLX) announced today that it has
notified holders of the 2.00% Convertible Exchange Senior Notes due
2037 (CUSIP No. 436440 AB7) issued November
23, 2010, and Wilmington Trust Company, the trustee, paying
agent and conversion agent for the notes, that holders are eligible
to convert the notes. This conversion right is subject to the
terms of the base indenture governing the notes dated as of
December 10, 2007, as supplemented by
the second supplemental indenture dated as of November 23, 2010 (collectively, the
indenture).
The conversion right has been triggered because the closing
price of the Company's common stock exceeded approximately
$29.94, which is 130% of the
conversion price for the notes, for at least 20 of the 30
consecutive trading days ending on September
30, 2016. As a result, the notes are convertible until
December 31, 2016, subject to the
terms, conditions and adjustments in the indenture and the notes.
The notes may continue to be convertible after December 31, 2016 if one or more conditions
specified in the indenture are satisfied during future measurement
periods.
The current conversion rate for the notes is 43.4216 shares of
the Company's common stock per $1,000
principal amount outstanding, which is equivalent to a conversion
price, as defined in the indenture, of approximately $23.03 per share. The Company may elect to
satisfy its conversion obligation in shares of common stock, cash,
or a combination of cash and shares in accordance with the terms,
procedures and conditions outlined in the indenture and the
notes.
None of the Company, its board of directors, or employees has
made, or is making, any representation or recommendation to any
holder of the notes as to whether or not to exercise the conversion
right.
Holders of the notes who have questions or wish to exercise
their conversion right should contact Wilmington Trust Company
at:
Wilmington Trust Company
Rodney Square North
1100 North Market Street
Wilmington, DE 19890
Attention: Workflow Management, 5th Floor
Telephone: (302) 636-6470
A complete explanation of the conversion right, as well as the
procedures required to convert notes, is set forth in the
indenture. Holders are urged to review the conversion
procedures contained in the notes and the indenture. The base
indenture was filed as Exhibit 4.1 to the Company's Current Report
on Form 8-K filed with the Securities and Exchange Commission on
December 10, 2007. The second
supplemental indenture was filed as Exhibit 4.1 to the Company's
Current Report on Form 8-K filed with the Securities and Exchange
Commission on November 18, 2010.
About Hologic
Hologic, Inc. is a leading developer, manufacturer and supplier
of premium diagnostic products, medical imaging systems and
surgical products. The Company's core business units focus on
diagnostics, breast health, GYN surgical, and skeletal health. With
a unified suite of technologies and a robust research and
development program, Hologic is dedicated to The Science of Sure.
For more information on Hologic, visit www.hologic.com.
Hologic and associated logos are trademarks and/or registered
trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
Contact
Michael Watts
Vice President, Investor Relations and
Corporate Communications
(858) 410-8588
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/hologic-delivers-notice-that-holders-of-200-convertible-exchange-senior-notes-due-2037-are-eligible-to-convert-300337736.html
SOURCE Hologic, Inc.